Overview
- In metastatic ovarian cancer mouse models, pairing the IL-12 nanoparticles with checkpoint inhibitors eliminated tumors in more than 80% of treated animals.
- Nanoparticles alone cleared disease in roughly 30% of mice while boosting T cell infiltration in the tumor microenvironment.
- The liposomal particles tether IL-12 via a stable maleimide linker and use a poly‑L‑glutamate coating to target tumor cells and release cytokine over about a week.
- Cured mice rejected new tumor cells five months later, indicating durable antitumor immune memory.
- Researchers report the work as preclinical and are pursuing scale-up and a potential spinout through MIT’s Deshpande Center following publication in Nature Materials.